Blend Innovative Growth & Defense With Healthcare ETFs

Traditionally speaking, investors look to gain targeted healthcare exposure as a means of portfolio defense. Today, healthcare companies offer compelling long-term growth through innovative developments like GLP-1 sales, AI, surgical robotics, precision oncology, and more. The State Street Health Care Select Sector SPDR ETF (XLV) offers low-cost access to health care companies, with the added benefit of a potent track record. Recent insights from the team at State Street Investment Management examined the opportunity set within the healthcare sector. The report indicated that while healthcare still has defensive potency, it is also seeing more long-term growth opportunities due to innovation within the sector. Innovation in the healthcare field is happening on multiple fronts. State Street noted that GLP-1 sales are continuing to grow and are expected to hit $190 billion by 2035. Meanwhile, AI adoption is proving to be highly useful in the drug development process for pharmaceutical companies. The innovation isn’t stopping there, either. Gene therapies, precision oncology, surgical robotics, and many other tools are reshaping the growth opportunities within the healthcare sector.

Healthcare Innovation Comes Alongside Traditional Defense Of course, this is all playing out while healthcare companies offer significant defensive advantages. Demand for healthcare is fairly inelastic, even amid inflation and rising prices. After all, when folks are sick, spending money on medicine and hospital treatments is often not really an option. “The next growth cycle is unlikely to mirror the previous one, but healthcare remains one of the few sectors capable of combining defensive characteristics with innovation-led growth, making it a valuable source of diversification within equity portfolios — and one with a growing innovation tilt that may offer the potential for a more competitive performance profile,” State Street said in the report.

Putting this all together, the mix of long-term growth and defensive stability makes the healthcare sector one worth considering tilting into in today’s landscape. As macroeconomic risks persist, healthcare stocks can protect against inflation while tackling long-term growth through innovation. This opportunity set can bode well for the State Street Health Care Select Sector SPDR ETF (XLV). XLV offers access to the healthcare companies within the S&P 500. Many of these companies, such as Eli Lilly (LLY), are among those that are best-positioned to benefit from growth in the healthcare sector. The fund’s recent track record may also add to the case for leaning into healthcare. As of August 31, 2026, XLV’s NAV has risen 26.20%, year to date.